Advertisements


Erytech Pharma confirms strategic focus of eryaspase on solid tumors

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2018

Erytech Pharma confirms strategic focus of eryaspase on solid tumors

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2018

ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update

Conference call and webcast scheduled for Tuesday, September 11that 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second line pan.....»»

Category: earningsSource: benzingaSep 10th, 2018

Perrigo plans to separate prescription pharma business

Perrigo Co Plc said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent......»»

Category: topSource: reutersAug 9th, 2018

Flex Pharma to focus resources on assessing strategic alternatives

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Erytech Pharma to present data from Phase 2/3 trial of eryaspase at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2018

Vanda Pharma Nails Midstage Gastroparesis Study

Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis......»»

Category: blogSource: 247wallstDec 3rd, 2018

Key Pharma Players With HIV Focus Ahead of World Aids Day

Zacks.....»»

Category: topSource: redinewsNov 30th, 2018

Wall Street set for an upbeat open as Fed Chair speech looms; trade in focus

U.S. stock index futures posted solid gains ahead of Wednesday's open......»»

Category: topSource: moneycentralNov 28th, 2018

Additional Late-Stage Study Confirms Efficacy, Safety Of GW Pharma"s Epidiolex

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. read more.....»»

Category: blogSource: benzingaNov 26th, 2018

What"s in Store for GW Pharma (GWPH) This Earnings Season?

On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus wi.....»»

Category: smallbizSource: nytNov 23rd, 2018

Total Pharma Tracker"s Daily BioPharma Focus: Biohaven Migraine Pipeline And Risk Factors

Total Pharma Tracker"s Daily BioPharma Focus: Biohaven Migraine Pipeline And Risk Factors.....»»

Category: topSource: seekingalphaNov 21st, 2018

Total Pharma Tracker"s Daily BioPharma Focus: Tesaro, The Takeover Rumor Stock

Total Pharma Tracker"s Daily BioPharma Focus: Tesaro, The Takeover Rumor Stock.....»»

Category: topSource: seekingalphaNov 19th, 2018

YY Enters Strategic Agreement With Xiaomi -- Here Are All The Takeaways From Another Solid Quarter

YY Enters Strategic Agreement With Xiaomi -- Here Are All The Takeaways From Another Solid Quarter.....»»

Category: topSource: seekingalphaNov 16th, 2018

Here"s Why You Should Buy Integer Holdings (ITGR) Stock Now

Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTec.....»»

Category: worldSource: nytNov 14th, 2018

Erytech Pharma S.A. ADS (ERYP) CEO Gil Beyen on Q3 2018 Results - Earnings Call Transcript

Erytech Pharma S.A. ADS (ERYP) CEO Gil Beyen on Q3 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaNov 13th, 2018

ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update

Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ($170 million) as of September 30, 2018 LYON, France and CAM.....»»

Category: earningsSource: benzingaNov 12th, 2018

RPM Banks on Buyout & Expansion Plans, Costs on the Rise

RPM likely to benefit from cost-saving initiatives and continuous focus on strategic acquisitions amid rising costs. RPM International Inc.’s RPM cost-saving init.....»»

Category: dealsSource: nytNov 9th, 2018

Deckers" (DECK) Strategic Endeavors Remain Well on Track

Deckers (DECK) continues to focus on expanding brand assortments, introducing more innovative line of products, targeting consumers digitally along with optimizing omni-channel distribution. Deckers Outdoor Corporation&rs.....»»

Category: worldSource: nytNov 7th, 2018

Strategic Education (STRA) Q3 Earnings: What"s in the Cards?

Strategic Education's (STRA) solid new student enrollment and innovative app-based courses are likely to boost Q3 results. Strategic Education Inc. STRA is slated to report third-quarter.....»»

Category: smallbizSource: nytNov 6th, 2018

Strayer parent launches seed-stage venture fund. Its first focus: better writing.

Herndon-based Strategic Education Inc., parent company of Strayer and Capella universities, announced Friday that it has launched a seed-stage venture fund to support tech start-ups with an educational bent. While it didn’t put a dollar figure o.....»»

Category: topSource: bizjournalsOct 29th, 2018